Ipsen: UBS upgrades stock
(CercleFinance.com) - UBS has upgraded its recommendation on Ipsen from "neutral" to "buy", with its price target raised sharply from E113 to E150, a new target that holds a potential 26% upside for the French pharmaceutical company's stock.
Seeing Ipsen as having " a superior growth profile but trading at a discount ", the broker sees " more room for a re-rating as Ipsen continuously".
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.